(PDF) Final Results of a Phase 1b Study of the Safety and

Final Results of a Phase 1b Study of the Safety and Efficacy of the PI3Kδ Inhibitor Acalisib (GS-9820) in Relapsed/Refractory Lymphoid Malignancies

Blood Cancer Journal - United States

doi 10.1038/s41408-018-0055-x

Full Text

Open PDF

Abstract

Available in full text

Date

February 1, 2018

Authors

Arnon P. Kater

Sanne H. Tonino

Marjolein Spiering

Martine E. D. Chamuleau

Roberto Liu

Adeboye Henry Adewoye

Jie Gao

Lyndah Dreiling

Yan Xin

Jeanette K. Doorduijn

Marie José Kersten

Publisher

Springer Science and Business Media LLC

Related search

Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

American Journal of Hematology

Hematology

2019

English

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Hematological Oncology

English

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial

Hematological Oncology

English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

English

Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study

Hematological Oncology

English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology

Hematology

2019

English

Efficacy of the Oral mTORC1 Inhibitor Everolimus in Relapsed or Refractory Indolent Lymphoma

American Journal of Hematology

Hematology

2017

English

Elara: A Phase 2 Trial Investigating the Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory/Relapsed Follicular Lymphoma

Hematological Oncology

English

Amanote Research

Final Results of a Phase 1b Study of the Safety and Efficacy of the PI3Kδ Inhibitor Acalisib (GS-9820) in Relapsed/Refractory Lymphoid Malignancies

Blood Cancer Journal - United States

doi 10.1038/s41408-018-0055-x

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

Efficacy of the Oral mTORC1 Inhibitor Everolimus in Relapsed or Refractory Indolent Lymphoma

Elara: A Phase 2 Trial Investigating the Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory/Relapsed Follicular Lymphoma